220 related articles for article (PubMed ID: 22674792)
1. Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.
Stratford AL; Reipas K; Hu K; Fotovati A; Brough R; Frankum J; Takhar M; Watson P; Ashworth A; Lord CJ; Lasham A; Print CG; Dunn SE
Stem Cells; 2012 Jul; 30(7):1338-48. PubMed ID: 22674792
[TBL] [Abstract][Full Text] [Related]
2. Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).
Reipas KM; Law JH; Couto N; Islam S; Li Y; Li H; Cherkasov A; Jung K; Cheema AS; Jones SJ; Hassell JA; Dunn SE
Oncotarget; 2013 Feb; 4(2):329-45. PubMed ID: 23593654
[TBL] [Abstract][Full Text] [Related]
3. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.
Stratford AL; Fry CJ; Desilets C; Davies AH; Cho YY; Li Y; Dong Z; Berquin IM; Roux PP; Dunn SE
Breast Cancer Res; 2008; 10(6):R99. PubMed ID: 19036157
[TBL] [Abstract][Full Text] [Related]
4. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.
Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR
Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895
[TBL] [Abstract][Full Text] [Related]
5. MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition.
Astanehe A; Finkbeiner MR; Krzywinski M; Fotovati A; Dhillon J; Berquin IM; Mills GB; Marra MA; Dunn SE
Oncogene; 2012 Oct; 31(41):4434-46. PubMed ID: 22249268
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer.
Shiota M; Yokomizo A; Takeuchi A; Itsumi M; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Prostate; 2014 Jun; 74(9):959-69. PubMed ID: 24740858
[TBL] [Abstract][Full Text] [Related]
7. Overcoming resistance to Sonic Hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma.
Pambid MR; Berns R; Adomat HH; Hu K; Triscott J; Maurer N; Zisman N; Ramaswamy V; Hawkins CE; Taylor MD; Dunham C; Guns E; Dunn SE
Pediatr Blood Cancer; 2014 Jan; 61(1):107-15. PubMed ID: 23940083
[TBL] [Abstract][Full Text] [Related]
8. The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiation-induced apoptosis and mediates senescence via RSK- and p53-independent accumulation of p21WAF1/CIP1.
Neise D; Sohn D; Stefanski A; Goto H; Inagaki M; Wesselborg S; Budach W; Stühler K; Jänicke RU
Cell Death Dis; 2013 Oct; 4(10):e859. PubMed ID: 24136223
[TBL] [Abstract][Full Text] [Related]
9. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
Hu K; Law JH; Fotovati A; Dunn SE
Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous Targeting of RSK and AKT Efficiently Inhibits YB-1-Mediated Repair of Ionizing Radiation-Induced DNA Double-Strand Breaks in Breast Cancer Cells.
Lettau K; Zips D; Toulany M
Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):567-580. PubMed ID: 32931865
[TBL] [Abstract][Full Text] [Related]
11. Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance.
To K; Fotovati A; Reipas KM; Law JH; Hu K; Wang J; Astanehe A; Davies AH; Lee L; Stratford AL; Raouf A; Johnson P; Berquin IM; Royer HD; Eaves CJ; Dunn SE
Cancer Res; 2010 Apr; 70(7):2840-51. PubMed ID: 20332234
[TBL] [Abstract][Full Text] [Related]
12. Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.
Ludwik KA; Campbell JP; Li M; Li Y; Sandusky ZM; Pasic L; Sowder ME; Brenin DR; Pietenpol JA; O'Doherty GA; Lannigan DA
Mol Cancer Ther; 2016 Nov; 15(11):2598-2608. PubMed ID: 27528706
[TBL] [Abstract][Full Text] [Related]
13. Divergent off-target effects of RSK N-terminal and C-terminal kinase inhibitors in cardiac myocytes.
Stathopoulou K; Schobesberger S; Bork NI; Sprenger JU; Perera RK; Sotoud H; Geertz B; David JP; Christ T; Nikolaev VO; Cuello F
Cell Signal; 2019 Nov; 63():109362. PubMed ID: 31344438
[TBL] [Abstract][Full Text] [Related]
14. BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo.
Sapkota GP; Cummings L; Newell FS; Armstrong C; Bain J; Frodin M; Grauert M; Hoffmann M; Schnapp G; Steegmaier M; Cohen P; Alessi DR
Biochem J; 2007 Jan; 401(1):29-38. PubMed ID: 17040210
[TBL] [Abstract][Full Text] [Related]
15. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation.
Smith JA; Poteet-Smith CE; Xu Y; Errington TM; Hecht SM; Lannigan DA
Cancer Res; 2005 Feb; 65(3):1027-34. PubMed ID: 15705904
[TBL] [Abstract][Full Text] [Related]
16. Interactions between FGFR2 and RSK2-implications for breast cancer prognosis.
Czaplinska D; Mieczkowski K; Supernat A; Skladanowski AC; Kordek R; Biernat W; Zaczek AJ; Romanska HM; Sadej R
Tumour Biol; 2016 Oct; 37(10):13721-13731. PubMed ID: 27476168
[TBL] [Abstract][Full Text] [Related]
17. Fisetin targets YB-1/RSK axis independent of its effect on ERK signaling: insights from in vitro and in vivo melanoma models.
Sechi M; Lall RK; Afolabi SO; Singh A; Joshi DC; Chiu SY; Mukhtar H; Syed DN
Sci Rep; 2018 Oct; 8(1):15726. PubMed ID: 30356079
[TBL] [Abstract][Full Text] [Related]
18. Substituted pteridinones as p90 ribosomal S6 protein kinase (RSK) inhibitors: A structure-activity study.
Casalvieri KA; Matheson CJ; Backos DS; Reigan P
Bioorg Med Chem; 2020 Mar; 28(5):115303. PubMed ID: 31982240
[TBL] [Abstract][Full Text] [Related]
19. Extracellular Signal-regulated Kinase (ERK)-dependent Phosphorylation of Y-Box-binding Protein 1 (YB-1) Enhances Gene Expression in Granulosa Cells in Response to Follicle-stimulating Hormone (FSH).
Donaubauer EM; Hunzicker-Dunn ME
J Biol Chem; 2016 Jun; 291(23):12145-60. PubMed ID: 27080258
[TBL] [Abstract][Full Text] [Related]
20. Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability.
Law JH; Li Y; To K; Wang M; Astanehe A; Lambie K; Dhillon J; Jones SJ; Gleave ME; Eaves CJ; Dunn SE
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
